Overview

Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing

Status:
Active, not recruiting

Trial end date:
2023-08-01

Target enrollment:

Participant gender:

Summary

This is a phase 2 trial seeking to define the safety and activity of gemcitabine, cisplatin, plus nivolumab as neoadjuvant therapy in patients with muscle-invasive bladder cancer and to define the role of clinical complete response in predicting benefit in patients opting to avoid cystectomy.

Phase:

Phase 2

Details

Lead Sponsor:

Matthew Galsky

Collaborators:

Bristol-Myers Squibb
Icahn School of Medicine at Mount Sinai

Treatments:

Antibodies, Monoclonal
Cisplatin
Gemcitabine
Nivolumab